source
- Novo Nordisk shares slide 6% after Wegovy pill sales miss despite earnings beatNovo Nordisk reported second‑quarter results that beat both revenue and profit forecasts, posting a profit of $5.15 billion. The company’s oral Wegovy obesity pill generated $496 million in sales,…
- BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demandBioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…